Section Arrow
KRRO.NASDAQ
- Korro Bio
Quotes are at least 15-min delayed:2025/06/02 21:39 EDT
Last
 10.8
-0.62 (-5.43%)
Day High 
12.15 
Prev. Close
11.42 
1-M High
22.15 
Volume 
608.72K 
Bid
10.6
Ask
11.4
Day Low
10.29 
Open
11.59 
1-M Low
11 
Market Cap 
107.24M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 13.88 
20-SMA 14.86 
50-SMA 15.9 
52-W High 98 
52-W Low 10.29 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-9.42/-11.13
Enterprise Value
150.72M
Balance Sheet
Book Value Per Share
14.80
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
2.27M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OGENOragenics0.166+0.046+38.33%-- 
PSTVPlus Therapeutics0.3677+0.0808+28.16%-- 
NCNANuCana plc0.038+0.0027+7.65%-- 
PCSAProcessa Pharmaceuticals0.298+0.0055+1.88%-- 
BPMCBlueprint Medicines Corp127.79+26.44+26.09%-- 
Quotes are at least 15-min delayed:2025/06/02 21:39 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generatinga portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.